LENZ.US LENZ Therapeutics Inc

Healthcare Biotechnology USA Stocks
4.13 USD
Close of Nov 15, 2026
2.80 32.13
Market cap
USD 130M
P/E
-
P/B
0.68x
ROE
-72.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is LENZ.US undervalued?

Graham number

The Graham number of LENZ Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

LENZ Therapeutics Inc fundamental analysis

No fundamental analysis for LENZ Therapeutics Inc yet.

LENZ Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About LENZ Therapeutics Inc

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, Calif…

Full company profile